Generics· June 29, 2026 · 18 min read
Generic Xarelto Entry: Orange Book Patents and NADAC Price Erosion
By Ran Chen#Generics#Orange Book#Generic Entry
Topic
DOAC
Direct oral anticoagulants, factor Xa inhibitors, apixaban, rivaroxaban, edoxaban, dabigatran, formulary, and access.
Generics· June 23, 2026 · 17 min read
Eliquis Generic: Why US Entry is Delayed to April 2028 Despite IRA Cuts
By Ran Chen#Generic Entry#FDA Approval#Orange Book
Evidence· June 15, 2026 · 11 min read
DOACs in FAERS: 330,426 adverse-event reports by the numbers
By Ran Chen#DOAC#Real-World Evidence#Label Warnings
Pricing & Access· May 23, 2026 · 10 min read
DOAC access landscape: Eliquis, Xarelto, Pradaxa, and Savaysa in 2026
By Ran Chen#DOAC#Coverage Access#Prior Authorization
Pricing & Access· May 16, 2026 · 11 min read
Eliquis vs Xarelto: label, access, and payer coverage compared
By Ran Chen#DOAC#Anticoagulant#Prior Authorization